Short answer
TuHURA Biosciences, Inc./NV (HURA) filed its Q3 2026 10-Q quarterly report on Nov 13, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$6M
- +9.8% YoY · +30.5% QoQ
- EPS (diluted)
- −$0.10
- +28.6% YoY · +28.6% QoQ
Source: XBRL data from the TuHURA Biosciences, Inc./NV (HURA) Q3 2026 10-Q on SEC EDGAR. USD.
TuHURA Biosciences, Inc./NV Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, with no products approved for sale
- Net loss $6.4M vs $7.1M YoY, operating loss $5.7M vs $6.7M
- Best program TBS-2025 R&D $0.4M, up $0.1M; IFx-2.0 $1.1M, down $0.5M
- Cash $1.9M; operating cash use $18.1M, financing cash provided $16.5M
- Runway into 2028 projected; additional funding needed, with clinical and development costs expected to increase substantially
Risk Factors
- No material changes to previously disclosed risk factors since the 2025 Form 10-K
- No newly added risk factor identified this quarter
- Carried-forward risks remain those disclosed in the 2025 Form 10-K and March 31, 2026 Form 10-Q
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other TuHURA Biosciences, Inc./NV quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.